Loading…
RANI
Rani Therapeutics Holdings, Inc.
NASDAQ· Healthcare· Biotechnology· CUSIP 753018100
$0.84-1.66%Price as of Aug 29, 18:39 UTC · updated once a day, after the close
Key metrics
- Market cap
- $118.04M
- P/E
- —
- Forward P/E
- —
- P/B
- 2.9x
- Dividend yield
- —
- Payout
- —
- EPS
- -$0.13
- ROE
- -172.15%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 0.69
- 52-week high
- $3.87
- 52-week low
- $0.44
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -96.7% over 5Y.
today you would have $42.60▼ -95.7%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $1.35 | $1.37 | $3.32 | $5.90 | |
| P/S | — | 80.7x | 44.6x | — | — |
| P/B | 5.4x | 4.0x | 23.0x | 6.7x | 4.0x |
| EPS | -$0.45 | -$1.05 | -$1.33 | -$1.28 | |
| Profit margin | — | -1817.09% |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| ANIXAnixa Biosciences Inc | $3.48 | — | 8.1x | — | -71.97% | $118.4M |
| JYNTJOINT Corp | $8.38 | 59.9x | 7.2x | — | 10.62% | $118.52M |
| QUCYQuantum Cyber N.V. | $1.42 | — | 1.7x | — | -212.53% | $119.38M |
| GNLXGENELUX Corp | $2.66 |
About the company
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat rheumatoid arthritis; RT-116 which is in discovery stage for the treatment of obesity; RT-117 for rare diseases; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The company has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity; Chugai Pharmaceutical Co., Ltd. to commercialize the Chugai Product combining Chugai's Compound, which is in development for hemophilia, and the RaniPill HC oral delivery device for use in humans; and has a research and development collaboration with PegBio Co., Ltd. to expand obesity pipeline across multiple novel candidates. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
- 69
- San Jose, United States
Company description provided by Yahoo Finance.